Phase 3 Recruiting Academic/Other
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among prem…
Sponsor: NRG Oncology
NCT ID: NCT05879926
Sites in Maryland: - UM Upper Chesapeake Hematology and Oncology - Aberdeen — Aberdeen, Maryland
- Luminis Health Anne Arundel Medical Center — Annapolis, Maryland
- University of Maryland/Greenebaum Cancer Center — Baltimore, Maryland
- Mercy Medical Center — Baltimore, Maryland
- Greater Baltimore Medical Center — Baltimore, Maryland
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer. Olaparib is a poly…
Sponsor: NRG Oncology
NCT ID: NCT06580314
Sites in Maryland: - Johns Hopkins University/Sidney Kimmel Cancer Center — Baltimore, Maryland
- Walter Reed National Military Medical Center — Bethesda, Maryland
- Christiana Care - Union Hospital — Elkton, Maryland
Phase 3 Recruiting Network
This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it dev…
Sponsor: Children's Oncology Group
NCT ID: NCT03067181
Sites in Maryland: - University of Maryland/Greenebaum Cancer Center — Baltimore, Maryland
- Sinai Hospital of Baltimore — Baltimore, Maryland
- Johns Hopkins University/Sidney Kimmel Cancer Center — Baltimore, Maryland
- Walter Reed National Military Medical Center — Bethesda, Maryland
Phase 3 Recruiting Industry
This is a clinical study that has three parts. It is testing a potential new medicine called Sofetabart Mipitecan (Sofe-M) for people with certain types of ovarian, peritoneal, and fallopian tube cancers. Part A enrolls participants with p…
Sponsor: Eli Lilly and Company
NCT ID: NCT07213804
Sites in Maryland: - Greater Baltimore Medical Center — Baltimore, Maryland
- Sinai Hospital Of Baltimore — Baltimore, Maryland
Phase 3 Recruiting Industry
The purpose of this study is to evaluate INCB123667 versus investigator's choice of chemotherapy in participants with platinum-resistant ovarian cancer with cyclin E1 overexpression.
Sponsor: Incyte Corporation
NCT ID: NCT07214779
Sites in Maryland: - Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins — Baltimore, Maryland
- Holy Cross Hospital — Silver Spring, Maryland
Phase 3 Recruiting Industry
The intention of the study is to demonstrate superiority of AZD5335 versus standard of care by assessment of progression-free survival (PFS) in women with high-grade, platinum-resistant epithelial ovarian, fallopian tube, or primary perito…
Sponsor: AstraZeneca
NCT ID: NCT07218809
Sites in Maryland: - Research Site — Towson, Maryland
Phase 3 Recruiting Industry
This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (ICT) in subjects with recurrent LGSOC who have progressed on a prior platinum-based therapy.
Sponsor: Verastem, Inc.
NCT ID: NCT06072781
Sites in Maryland: - Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — Baltimore, Maryland
Phase 3 Recruiting Industry
The OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab compared to the Active Comparator Arm with Physician's Choice…
Sponsor: Genelux Corporation
NCT ID: NCT05281471
Sites in Maryland: - Holy Cross Hospital — Silver Spring, Maryland
Phase 3 Recruiting Industry
This Phase 3 study is designed to investigate the safety, diagnostic performance, and clinical usefulness of Gleolan for the real-time detection and visualization of epithelial ovarian cancer tumors during debulking surgery. The study is p…
Sponsor: NX Development Corp
NCT ID: NCT05804370
Sites in Maryland: - Luminis Health Anne Arundel Medical Center — Annapolis, Maryland
- University of Maryland — Baltimore, Maryland
Phase 2 Recruiting NIH
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564377
Sites in Maryland: - University of Maryland/Greenebaum Cancer Center — Baltimore, Maryland
- Walter Reed National Military Medical Center — Bethesda, Maryland
- National Institutes of Health Clinical Center — Bethesda, Maryland
- UPMC Western Maryland — Cumberland, Maryland
Phase 2 Recruiting Industry
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess the safety and efficacy of neoadjuvant carboplatin and mirvetuximab soravtansine in participants with fo…
Sponsor: AbbVie
NCT ID: NCT06890338
Sites in Maryland: - University of Maryland, Baltimore /ID# 275308 — Baltimore, Maryland
- Holy Cross Hospital /ID# 275872 — Silver Spring, Maryland
Phase 2 Recruiting Industry
This is a multi-part Phase 2 study to evaluate the efficacy and safety of azenosertib (ZN-c3) in subjects with Platinum-Resistant, High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. Part 2 of the study will be conduct…
Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
NCT ID: NCT05128825
Sites in Maryland: - Site 0146 - Maryland Oncology Hematology, PA — Rockville, Maryland
Phase 2 Recruiting Industry
This study will evaluate the safety and efficacy of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer (PROC) With Cyclin E1 Overexpression.
Sponsor: Incyte Corporation
NCT ID: NCT07023627
Sites in Maryland: - Greater Baltimore Medical Center — Baltimore, Maryland
Phase 1, Phase 2 Recruiting Industry
This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) o…
Sponsor: Genmab
NCT ID: NCT05579366
Sites in Maryland: - USOR Maryland Oncology Hematology — Rockville, Maryland
Phase 2 Recruiting Industry
A Phase 2 study to evaluate the safety and efficacy of TORL-1-23 in patients with advanced ovarian cancer.
Sponsor: TORL Biotherapeutics, LLC
NCT ID: NCT06690775
Sites in Maryland: - SCRI - Maryland Oncology Hematology, P.A. — Annapolis, Maryland
Phase 1, Phase 2 Recruiting Industry
The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of DZR123 (Tulmimetostat, CPI-0209), both as monotherapy and in comb…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT04104776
Sites in Maryland: - University of Maryland Medical Ctr — Baltimore, Maryland
Phase 2 Recruiting Industry
This is a Phase 2, multicenter, open-label, single-arm study to evaluate the efficacy and safety of sapanisertib and serabelisib (PIKTOR) with paclitaxel in participants with advanced or recurrent endometrial cancer.
Sponsor: Faeth Therapeutics
NCT ID: NCT06463028
Sites in Maryland: - Maryland Oncology Hematology, P.A. — Brandywine, Maryland
Phase 2 Recruiting Industry
A Phase II, Multicenter, Open-Label Trial of DB-1311 in combination with BNT327 or DB-1305 in Participants with Advanced/Metastatic Solid Tumors
Sponsor: DualityBio Inc.
NCT ID: NCT06953089
Sites in Maryland: - USA11-0 — Bethesda, Maryland
Phase 1, Phase 2 Recruiting Industry
This is a first-in-human phase I/II study to examine the safety, tolerability and preliminary efficacy of VLS-1488 in subjects with advanced cancers.
Sponsor: Volastra Therapeutics, Inc.
NCT ID: NCT05902988
Sites in Maryland: - Johns Hopkins Sidney Kimmel Comprehensive Cancer Center — Baltimore, Maryland
Phase 2 Recruiting Industry
This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma \[cutaneous/acral\], squamous cell carc…
Sponsor: Daiichi Sankyo
NCT ID: NCT06172478
Sites in Maryland: - Johns Hopkins University — Baltimore, Maryland
Phase 1, Phase 2 Recruiting Industry
This is a 1:1 randomized, open label, multi-center phase I/II trial to evaluate the safety, dosing, efficacy, and biological activity of adding IMNN-001 to chemotherapy + BEV compared to chemotherapy + BEV alone.
Sponsor: Imunon
NCT ID: NCT05739981
Sites in Maryland: - Johns Hopkins Medicine SKCCC — Baltimore, Maryland
Phase 1, Phase 2 Recruiting Industry
ATLAS-101 is a Phase I/II clinical trial of AMXI-5001 in adult participants with advanced malignancies who have previously failed other therapies. The study has two phases. The purpose of Phase I (Dose Escalation) is to confirm the appropr…
Sponsor: AtlasMedx, Incorporated
NCT ID: NCT04503265
Sites in Maryland: - Johns Hopkins — Baltimore, Maryland
Phase 2 Recruiting Academic/Other
This is a phase 2 study to test the effectiveness (anti-tumor activity) of the combination of the study drugs, Senaparib and Temozolomide, in patients with clear cell or endometrioid ovarian cancers that have ARID1A pathologic variants.
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT ID: NCT06617923
Sites in Maryland: - Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — Baltimore, Maryland
Phase 1, Phase 2 Recruiting NIH
Background: In a new cancer therapy, researchers take a person s blood, select a certain white blood cell to grow in the lab, and then change the genes of these cells using a virus. The cells are then given back to the person. This is call…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT02830724
Sites in Maryland: - National Institutes of Health Clinical Center — Bethesda, Maryland
Phase 2 Recruiting NIH
Background: The NCI Surgery Branch has developed an experimental therapy that involves taking white blood cells from patients' tumors, growing them in the laboratory in large numbers, and then giving the cells back to the patient. These ce…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT01174121
Sites in Maryland: - National Institutes of Health Clinical Center — Bethesda, Maryland